Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Agile Therapeutics Inc. AGRX

Alternate Symbol(s):  AGXRW

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.


Recent & Breaking News (NDAQ:AGRX)

Agile Therapeutics Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Chief Medical Officer

GlobeNewswire August 17, 2020

Agile Therapeutics to Participate in Maxim Group's Leading Innovators in Women's Health Virtual Conference

GlobeNewswire August 11, 2020

Agile Therapeutics Reports Second Quarter 2020 Financial Results

GlobeNewswire August 11, 2020

Agile Therapeutics to Host Second Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, August 11, 2020

GlobeNewswire July 21, 2020

Agile Therapeutics to Join Russell 3000® and 2000® Indexes

GlobeNewswire June 16, 2020

Agile Therapeutics to Participate in Virtual Fireside Chat as part of the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2020

GlobeNewswire May 11, 2020

Agile Therapeutics Reports First Quarter 2020 Financial Results

GlobeNewswire May 5, 2020

Agile Therapeutics to Host First Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, May 5, 2020

GlobeNewswire April 23, 2020

Agile Therapeutics Announces Changes to its Board of Directors

GlobeNewswire April 22, 2020

Agile Therapeutics, Inc. (Nasdaq: AGRX) to Ring Nasdaq Stock Market Closing Bell on Wednesday, February 26, 2020

GlobeNewswire February 25, 2020

Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock

GlobeNewswire February 21, 2020

Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

GlobeNewswire February 20, 2020

Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire February 20, 2020

FDA Approves Agile Therapeutics, Inc.'s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System - A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin

GlobeNewswire February 14, 2020

Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors

GlobeNewswire February 10, 2020

Agile Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco

GlobeNewswire January 6, 2020

Agile Therapeutics Strengthens Commercial Leadership Team

GlobeNewswire January 2, 2020

Agile Therapeutics to Present at Biotech Showcase(TM) 2020 in San Francisco

GlobeNewswire December 19, 2019

Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period

GlobeNewswire November 14, 2019

Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15)

GlobeNewswire October 30, 2019